News
NNVC
1.330
+1.53%
0.020
NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’
TipRanks · 4d ago
NanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibugyo Ebolavirus And Other Ebola Viruses To Begin Soon In The Democratic Republic Of Congo
Benzinga · 4d ago
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
Barchart · 5d ago
Weekly Report: what happened at NNVC last week (0810-0814)?
Weekly Report · 5d ago
Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), BridgeBio Pharma (BBIO) and NanoViricides (NNVC)
TipRanks · 08/11 13:31
NanoViricides receives regulatory approval for Phase II trial of NV-387
TipRanks · 08/10 12:35
NanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For Ebola
Benzinga · 08/10 12:34
Weekly Report: what happened at NNVC last week (0803-0807)?
Weekly Report · 08/10 10:27
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
Barchart · 08/10 07:30
Weekly Report: what happened at NNVC last week (0727-0731)?
Weekly Report · 08/03 10:27
NanoViricides Announces $3.8 Million Registered Direct Offering
TipRanks · 07/30 10:28
NanoViricides awaits regulatory approval to being Phase II trial of NV-387
TipRanks · 07/28 12:40
NanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo
Benzinga · 07/28 12:35
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
Barchart · 07/28 07:30
Weekly Report: what happened at NNVC last week (0720-0724)?
Weekly Report · 07/27 10:32
NanoViricides announces $3.8M registered direct offering; shares down
Seeking Alpha · 07/24 12:23
NanoViricides prices $3.8M registered direct offering
TipRanks · 07/24 12:10
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 07/24 12:05
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
Barchart · 07/24 07:00
NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial
TipRanks · 07/22 12:56
More
Webull provides a variety of real-time NNVC stock news. You can receive the latest news about Nanoviricides through multiple platforms. This information may help you make smarter investment decisions.
About NNVC
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.